Literature DB >> 31284763

Amyotrophic lateral sclerosis as a multi-step process: an Australia population study.

Steve Vucic1, Henk-Jan Westeneng2, Ammar Al-Chalabi3,4, Leonard H Van Den Berg2, Paul Talman5, Matthew C Kiernan6.   

Abstract

Objective: This study sought to investigate whether a multistep process was also evident in an Australian amyotrophic lateral sclerosis (ALS) population.
Methods: Mortality rates for ALS patients (years 2007-2016) were obtained from the Australian Institute of Health and Welfare (AIHW). The log incidence of ALS, as reflected by crude mortality rates, was regressed against log of age disease onset.
Results: From a total population of 24 million, 6524 cases of ALS were identified. A linear relation between the log incidence and log age was identified, with r2 value of 0.99, indicating that ALS is a multistep process. The linear slope estimate was 5.0, suggesting that six steps were required for development of ALS. Conclusions: This study established a linear relationship between log incidence and log age onset in an Australia ALS population, consistent with a multistep process. Identification of these steps will likely be of therapeutic benefit in ALS.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; incidence; multi-step process

Mesh:

Year:  2019        PMID: 31284763     DOI: 10.1080/21678421.2018.1556697

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  8 in total

1.  Sporadic, late-onset, and multistage diseases.

Authors:  Anthony J Webster; Robert Clarke
Journal:  PNAS Nexus       Date:  2022-06-22

2.  cGAS and DDX41-STING mediated intrinsic immunity spreads intercellularly to promote neuroinflammation in SOD1 ALS model.

Authors:  Hong Yien Tan; Yean Kong Yong; Yuan Chao Xue; Huitao Liu; Tomomi Furihata; Esaki Muthu Shankar; Chen Seng Ng
Journal:  iScience       Date:  2022-05-13

3.  Is Exposure to BMAA a Risk Factor for Neurodegenerative Diseases? A Response to a Critical Review of the BMAA Hypothesis.

Authors:  Dunlop Ra; Banack Sa; Bishop Sl; Metcalf Js; Murch Sj; Davis DA; Stommel Ew; Karlsson O; Brittebo Eb; Chatziefthimiou Ad; Tan Vx; Guillemin Gg; Cox Pa; Mash Dc; Bradley Wg
Journal:  Neurotox Res       Date:  2021-02-06       Impact factor: 3.911

4.  Destination Amyotrophic Lateral Sclerosis.

Authors:  Matt Keon; Benjamin Musrie; Marcel Dinger; Samuel E Brennan; Jerran Santos; Nitin K Saksena
Journal:  Front Neurol       Date:  2021-03-29       Impact factor: 4.003

5.  A polymorphic transcriptional regulatory domain in the amyotrophic lateral sclerosis risk gene CFAP410 correlates with differential isoform expression.

Authors:  Jack N G Marshall; Alexander Fröhlich; Li Li; Abigail L Pfaff; Ben Middlehurst; Thomas P Spargo; Alfredo Iacoangeli; Bing Lang; Ammar Al-Chalabi; Sulev Koks; Vivien J Bubb; John P Quinn
Journal:  Front Mol Neurosci       Date:  2022-09-05       Impact factor: 6.261

6.  Phase 2 randomized placebo controlled double blind study to assess the efficacy and safety of tecfidera in patients with amyotrophic lateral sclerosis (TEALS Study): Study protocol clinical trial (SPIRIT Compliant).

Authors:  Steve Vucic; Julie Ryder; Linda Mekhael; Henderson Rd; Susan Mathers; Merilee Needham; Schultz Dw; Kiernan Mc
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

7.  Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study.

Authors:  Steve Vucic; Robert D Henderson; Susan Mathers; Merrilee Needham; David Schultz; Matthew C Kiernan
Journal:  Ann Clin Transl Neurol       Date:  2021-09-03       Impact factor: 4.511

8.  A Multi-Step Model of Parkinson's Disease Pathogenesis.

Authors:  Campbell Le Heron; Michael MacAskill; Deborah Mason; John Dalrymple-Alford; Tim Anderson; Toni Pitcher; Daniel Myall
Journal:  Mov Disord       Date:  2021-08-10       Impact factor: 9.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.